RxDoctor Payments Data

Eric Manheimer, MD

Clinical Cardiac Electrophysiology · West Nyack, NYNPI 1134368608

Payments from drug & device makers

$4,708in general payments, 2019–2025

Across 102 payments — averaging $46.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Biosense Webster, Inc.$2K
  • Medtronic$765
  • Abbott$109
  • Cardiovascular Systems Inc.$23
  • Sanofi-aventis U.S. LLC$20
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$4,708100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,708 in reported general payments places this provider in the 15th percentile of 214 clinical cardiac electrophysiology providers in New York.

See all clinical cardiac electrophysiology providers in New York

Medicare billing

Part B allowed, 2024
$360,541
Medicare patients
720
Services billed
3,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban336$333,875
XareltoRivaroxaban113$139,222
MultaqDronedarone Hcl22$32,812
Metoprolol Succinate407$4,973
Diltiazem 24hr Er (Cd)Diltiazem Hcl27$2,064
Ezetimibe12$1,548
Amiodarone Hcl66$1,071
Losartan Potassium137$1,051
Lisinopril110$1,047
Amlodipine Besylate167$939
Nifedipine ErNifedipine15$845
Rosuvastatin Calcium77$844
Metoprolol Tartrate146$807
Digoxin27$663
Atorvastatin Calcium120$641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCMultaq$20$32,81222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 214 clinical cardiac electrophysiology providers in New York.

Other clinical cardiac electrophysiology in West Nyack

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →